Back

Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy

European Journal of Preventive Cardiology

12 March 2024
Organised by: Logo
Read full article
ESC Journals PREVENTIVE CARDIOLOGY Risk Factors and Prevention

Contributors

Francesco Sbrana
Francesco Sbrana

Author

Toscana Gabriele Monasterio Foundation Pisa , Italy

Federico Bigazzi
Federico Bigazzi

Author

Carmen Corciulo
Carmen Corciulo

Author

Beatrice Dal Pino
Beatrice Dal Pino

Author

You may be interested in
thumbnail
Webinar
Lipoprotein(a): current role and future perspectives in cardiovascular medicine
31 October 2025
thumbnail
Congress Presentation
Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
27 August 2022
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025
thumbnail
Webinar
Lipid management pathways and ESC Guidelines
10 January 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources